Sökning: "tumour control"
Visar resultat 36 - 40 av 195 avhandlingar innehållade orden tumour control.
36. Head and Neck Cancer: Studies on microvessel density, radiation response and FDG PET
Sammanfattning : Treatment options of head and neck squamous cell carcinoma (HNSCC) usually include combinations of radiotherapy and surgery, and in some cases addition of chemotherapy. In locally advanced cases cure rates are low. Current prognostic factors cannot foresee the outcome for the individual patient. LÄS MER
37. Vascular endothelial growth factor in renal cell carcinoma
Sammanfattning : Background. Angiogenesis is essential for tumour growth. Vascular endothelial growth factor (VEGF) and its isoforms were investigated in relation to the clinical course in a large number of patients with renal cell carcinoma (RCC). Methods. LÄS MER
38. Indicators of colorectal cancer prognosis and response to preoperative radiotherapy
Sammanfattning : Colorectal cancer is one of the three most common malignant diseases in Sweden, with about 5,000 new cases each year. Thirty-five percent of these are rectal cancer, for which local recurrence after surgery has been a serious problem. The five-year survival rate in colorectal cancer has improved from about 40% in 1960 to 55% in 1995. LÄS MER
39. Outcome of preoperative radiotherapy in the treatment of cervical cancer with focus on protein expression and dosimetry
Sammanfattning : Treatment with preoperative intracavitary radiotherapy (ICRT) is used in cervical cancer with the intention to reduce the tumour burden and sterilize microscopic disease in the paracervical tissues. Preoperative ICRT is, however, a controversial treatment regime since it is unclear if addition of ICRT to surgery improves treatment outcome compared to surgery alone. LÄS MER
40. Urinary bladder carcinoma, preclinical and clinical studies on EGFR based targeting
Sammanfattning : Radical cystectomy with bilateral pelvic lymphadenectomy is the standard treatment for muscle-invasive transitional cell carcinoma of the urinary bladder. Despite presumably localised malignancies and efficacious management about 50% of patients will die within 5 years, the majority due to metastatic disease. LÄS MER